PET and PET/CT in endocrine tumours.
Functional information provided by PET tracers together with the superior image quality and the better data quantification by PET technology had a changing effect on the significance of nuclear medicine in medical issues. Recently introduced hybrid PET/CT systems together with the introduction of novel PET radiopharmaceuticals have contributed to the fact that nuclear medicine has become a growing diagnostic impact on endocrinology. In this review imaging strategies, different radiopharmaceuticals including the basic mechanism of their cell uptake, and the diagnostic value of PET and PET/CT in endocrine tumours except differentiated thyroid carcinomas will be discussed.
Dudczak
Robert
R
Department of Nuclear Medicine, Medical University of Vienna, Austria. robert.dudczak@meduniwien.ac.at
Traub-Weidinger
Tatjana
T
D002250:Carbon Radioisotopes; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives; D004701:Endocrine Gland Neoplasms / Q000000981:diagnostic imaging*; D019788:Fluorodeoxyglucose F18; D005710:Gallium Radioisotopes; D006801:Humans; D007090:Image Interpretation, Computer-Assisted / Q000379:methods; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed / Q000379:methods*
D002250:Carbon Radioisotopes; D005710:Gallium Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C043437:fluorodopa F 18; D004295:Dihydroxyphenylalanine